These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 8153308)

  • 61. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Makler PT
    J Nucl Med; 1997 Jul; 38(7):1173-4. PubMed ID: 9225819
    [No Abstract]   [Full Text] [Related]  

  • 62. PET-CT in the staging and treatment of non-small-cell lung cancer.
    Ibeas P; Cantos B; Gasent JM; Rodríguez B; Provencio M
    Clin Transl Oncol; 2011 Jun; 13(6):368-77. PubMed ID: 21680297
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolic staging of lung cancer.
    Berlangieri SU; Scott AM
    N Engl J Med; 2000 Jul; 343(4):290-2. PubMed ID: 10911013
    [No Abstract]   [Full Text] [Related]  

  • 64. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
    Scott WJ; Shepherd J; Gambhir SS
    Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Radiotherapy of lung cancer: Any room left for elective mediastinal irradiation in 2011?].
    Van Houtte P; Roelandts M; Mornex F
    Cancer Radiother; 2011 Oct; 15(6-7):509-13. PubMed ID: 21873096
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of lung cancer by 99mTc-tetrofosmin SPECT: comparison with [18F]FDG-PET.
    Tatsumi M; Yutani K; Nishimura T
    J Comput Assist Tomogr; 2000; 24(4):574-80. PubMed ID: 10966189
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer.
    Bury T; Barreto A; Daenen F; Barthelemy N; Ghaye B; Rigo P
    Eur J Nucl Med; 1998 Sep; 25(9):1244-7. PubMed ID: 9724372
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Possible role of FDG-PET in the evaluation of urologic malignancies.
    Bender H; Schomburg A; Albers P; Ruhlmann J; Biersack HJ
    Anticancer Res; 1997; 17(3B):1655-60. PubMed ID: 9179213
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.
    Steinert HC; Huch Böni RA; Buck A; Böni R; Berthold T; Marincek B; Burg G; von Schulthess GK
    Radiology; 1995 Jun; 195(3):705-9. PubMed ID: 7753998
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.
    Miyauchi T; Wahl RL
    Eur J Nucl Med; 1996 May; 23(5):517-23. PubMed ID: 8698055
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Cost effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan].
    Kubota K; Yamada S; Fukuda H; Tanida T; Saitou Y; Takahashi J; Yamada K
    Kaku Igaku; 1997 May; 34(5):329-36. PubMed ID: 9248260
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings.
    Hebert ME; Lowe VJ; Hoffman JM; Patz EF; Anscher MS
    Am J Clin Oncol; 1996 Aug; 19(4):416-21. PubMed ID: 8677917
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities.
    Lowe VJ; Hoffman JM; DeLong DM; Patz EF; Coleman RE
    J Nucl Med; 1994 Nov; 35(11):1771-6. PubMed ID: 7965154
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Observer variation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in mediastinal staging of non-small cell lung cancer as a function of experience, and its potential clinical impact.
    Smulders SA; Gundy CM; van Lingen A; Comans EF; Smeenk FW; Hoekstra OS;
    Mol Imaging Biol; 2007; 9(5):318-22. PubMed ID: 17610119
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case.
    Yasuda S; Raja S; Hubner KF
    Surg Today; 1995; 25(3):261-4. PubMed ID: 7640457
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
    Martin WH; Delbeke D; Patton JA; Sandler MP
    Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.
    Inokuma T; Tamaki N; Torizuka T; Magata Y; Fujii M; Yonekura Y; Kajiyama T; Ohshio G; Imamura M; Konishi J
    Radiology; 1995 May; 195(2):345-52. PubMed ID: 7724751
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Diagnosis of early cancer with positron emission tomography].
    Kubota K
    Nihon Rinsho; 1996 May; 54(5):1263-7. PubMed ID: 8965348
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Why most PET of lung and head-and-neck cancer will be PET/CT.
    Goerres GW; von Schulthess GK; Steinert HC
    J Nucl Med; 2004 Jan; 45 Suppl 1():66S-71S. PubMed ID: 14736837
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Staging of non-small-cell lung cancer with positron-emission tomography.
    Donckier JE; Roelants V; Pochet JM
    N Engl J Med; 2000 Nov; 343(21):1572; author reply 1572-3. PubMed ID: 11184751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.